Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsubrutinib and ABBV-599 (Elsubrutinib + Upadacitinib) LTE in Rheumatoid Arthritis
NCT03823378Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, double-blind trial of elsubrutinib in rheumatoid arthritis (RA) (6 arms), sponsored by AbbVie Inc. Primary endpoint: Number of Participants With Adverse Events up to 52 weeks. Started May 2019; status: terminated.
02
Drugs
elsubrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03823378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823378.